Cargando…

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer

Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed a pharmacogenomic analysis of MEKi-sensitive versus MEKi-resistant colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner, Steve, Vlachogiannis, Georgios, De Haven Brandon, Alexis, Valenti, Melanie, Box, Gary, Jenkins, Liam, Mancusi, Caterina, Self, Annette, Manodoro, Floriana, Assiotis, Ioannis, Robinson, Penny, Chauhan, Ritika, Rust, Alistair G., Matthews, Nik, Eason, Kate, Khan, Khurum, Starling, Naureen, Cunningham, David, Sadanandam, Anguraj, Isacke, Clare M., Kirkin, Vladimir, Valeri, Nicola, Whittaker, Steven R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462854/ https://www.ncbi.nlm.nih.gov/pubmed/30353166 http://dx.doi.org/10.1038/s41388-018-0554-z

Ejemplares similares

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2019)

polyClustR: defining communities of reconciled cancer subtypes with biological and prognostic significance
por: Eason, Katherine, et al.
Publicado: (2018)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
por: Sriskandarajah, Priya, et al.
Publicado: (2020)

A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine
por: Nyamundanda, Gift, et al.
Publicado: (2020)

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer
por: Georgiou, Alexandros, et al.
Publicado: (2021)

The 2(nd) Conference and Workshop of The Cancer Genome Atlas (TCGA) in India: Towards Team Science for Multi-omics Cancer Research in South Asia
por: Dixit, Santosh, et al.
Publicado: (2021)

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
por: Wilkins, Anna, et al.
Publicado: (2018)

KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes
por: McKenzie, Andrew J., et al.
Publicado: (2016)

The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing
por: Chong, Irene Y., et al.
Publicado: (2021)

Identification of Semaphorin 5A Interacting Protein by Applying Apriori Knowledge and Peptide Complementarity Related to Protein Evolution and Structure
por: Sadanandam, Anguraj, et al.
Publicado: (2008)

A Novel Statistical Method to Diagnose, Quantify and Correct Batch Effects in Genomic Studies
por: Nyamundanda, Gift, et al.
Publicado: (2017)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice
por: De Haven Brandon, Alexis, et al.
Publicado: (2020)

Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition
por: Sheppard, Sarah E., et al.
Publicado: (2023)

Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity
por: Heindl, Andreas, et al.
Publicado: (2018)

Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
por: Lyons, Yasmin A., et al.
Publicado: (2014)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution
por: Vidal-Cruchez, Olivia, et al.
Publicado: (2023)

MCAM: A Database to Accelerate the Identification of Functional Cell Adhesion Molecules
por: Sadanandam, Anguraj, et al.
Publicado: (2008)

Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses
por: Poudel, Pawan, et al.
Publicado: (2019)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2
por: Wong, Gabrielle S., et al.
Publicado: (2018)

The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
por: Ogishima, Juri, et al.
Publicado: (2018)

Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
por: Bhatt, Vrushank, et al.
Publicado: (2023)

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

A Cross-Species Analysis of a Mouse Model of Breast Cancer-Specific Osteolysis and Human Bone Metastases Using Gene Expression Profiling
por: Sadanandam, Anguraj, et al.
Publicado: (2011)

Identification and Characterization of Poorly Differentiated Invasive Carcinomas in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis
por: Hunter, Karen E., et al.
Publicado: (2013)

Cannabinoids in the landscape of cancer
por: Mangal, Nagina, et al.
Publicado: (2021)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
por: Hata, Aaron N, et al.
Publicado: (2017)

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
por: Cheon, Seul‐Ki, et al.
Publicado: (2018)

CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation
por: Griesmann, Heidi, et al.
Publicado: (2021)

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience
por: Khan, Khurum, et al.
Publicado: (2015)

Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials
por: Fontana, E, et al.
Publicado: (2019)

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway
por: Conti, Annalisa, et al.
Publicado: (2015)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
por: Lee, Michael S., et al.
Publicado: (2016)

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
por: Dompe, Nicholas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mj8dmd9at0lj9qmottbtu2lufh